Le Lézard
Classified in: Health, Business
Subject: BOARD OF DIRECTORS

Emblem Announces Appointment of Dan Milliard to its Board of Directors


TORONTO, May 02, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSX-V:EMC) (TSX-V:EMC.WT) ("Emblem" or the "Corporation") announces that the board of directors has appointed Dan Milliard to Emblem's board of directors replacing Mr. Lorne Gertner who resigned in April 2018. Mr. Milliard's appointment remains subject to the approval of the TSX Venture Exchange.

"I'm thrilled to welcome Dan to our Board," said Emblem CEO Nick Dean. "Dan has extensive board experience (as a Chartered Director), public markets experience, and business leadership experience. He will be invaluable to our Board, management team and shareholders as we enter the next phase of our growth strategy," added Dean.

In connection with the appointment, subject to receipt of the TSX Venture Exchange's approval of Mr. Milliard's appointment, the Corporation has approved the granting of 250,000 incentive stock options (the "Options") to Mr. Milliard. The Options are exercisable at a price of $1.51 per share for a period of five (5) years from the date of grant and shall vest over a period of three (3) years in equal annual installments of one-third of the Options on each of May 1, 2019, 2020 and 2021.

About Emblem

Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals ? cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol "EMC" on TSX Venture Exchange.

For further information contact:

Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
[email protected]

Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
[email protected]

Forward-looking statements

This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation, including, without limitation, the future results of operations, performance and achievements of the Corporation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Except as required by law, the Corporation disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Corporation from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


These press releases may also interest you

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...



News published on and distributed by: